What is HC Wainwright’s Forecast for ACXP FY2029 Earnings?

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) – Investment analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Acurx Pharmaceuticals in a research report issued on Wednesday, March 19th. HC Wainwright analyst E. Arce anticipates that the company will post earnings of ($0.57) per share for the year. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Acurx Pharmaceuticals’ current full-year earnings is ($0.89) per share.

Acurx Pharmaceuticals (NASDAQ:ACXP) last issued its quarterly earnings data on Monday, March 17th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02.

Acurx Pharmaceuticals Stock Performance

Shares of Acurx Pharmaceuticals stock opened at $0.42 on Thursday. The firm has a market cap of $9.33 million, a PE ratio of -0.39 and a beta of -1.71. The firm’s 50-day simple moving average is $0.69 and its 200-day simple moving average is $1.24. Acurx Pharmaceuticals has a 1 year low of $0.40 and a 1 year high of $3.33.

Insider Activity

In other Acurx Pharmaceuticals news, CEO David P. Luci acquired 49,261 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was acquired at an average price of $1.01 per share, with a total value of $49,753.61. Following the transaction, the chief executive officer now directly owns 1,097,458 shares in the company, valued at approximately $1,108,432.58. This represents a 4.70 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 29.60% of the company’s stock.

Institutional Investors Weigh In On Acurx Pharmaceuticals

An institutional investor recently raised its position in Acurx Pharmaceuticals stock. Prospect Financial Services LLC lifted its holdings in shares of Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) by 11.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 329,076 shares of the company’s stock after buying an additional 34,001 shares during the period. Prospect Financial Services LLC owned 1.93% of Acurx Pharmaceuticals worth $268,000 at the end of the most recent reporting period. 11.53% of the stock is currently owned by hedge funds and other institutional investors.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.